Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

To the editor: Primary symptomatic central nervous system (CNS) involvement as the initial manifestation of chronic lymphocytic leukemia (CLL) is exceedingly rare.[1][1] Treatment options in patients resistant to high-dose cytarabine or methotrexate chemotherapy are limited. Dasatinib is a tyrosine